KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity-Reference-Cited by-同舟云学术

KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity

Published:2020-07-22 Issue:8 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Poirel Laurent¹²³,Vuillemin Xavier¹,Juhas Mario¹,Masseron Amandine¹,Bechtel-Grosch Ursina⁴,Tiziani Simon⁵,Mancini Stefano⁶,Nordmann Patrice¹²³⁷

Affiliation:

1. Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland

2. Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland

3. INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland

4. Department of Trauma Surgery, University Hospital of Zürich, Zürich, Switzerland

5. Institute of Intensive Medicine, University Hospital Zürich, University of Zürich, Zürich, Switzerland

6. Institute of Medical Microbiology, University of Zürich, Zürich, Switzerland

7. Institut for Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland

Abstract

KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three-amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a sharp reduction of its carbapenemase activity.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00321-20

Reference23 articles.

1. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria

2. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

3. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

4. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

5. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid Detection of Ceftazidime/Avibactam Susceptibility/Resistance in Enterobacterales by Rapid CAZ/AVI NP Test;Emerging Infectious Diseases;2024-02

2. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health;Clinical Microbiology Reviews;2023-12-20

3. Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022);European Journal of Clinical Microbiology & Infectious Diseases;2023-11-21

4. Emergence of KPC-113 and KPC-114 variants in ceftazidime-avibactam-resistant Klebsiella pneumoniae belonging to high-risk clones ST11 and ST16 in South America;Microbiology Spectrum;2023-10-17

5. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland;European Journal of Clinical Microbiology & Infectious Diseases;2023-08-11